Core Points - Class action lawsuits have been filed on behalf of shareholders of several publicly-traded companies, with specific deadlines for filing lead plaintiff motions [1] RCI Hospitality Holdings, Inc. (NASDAQ: RICK) - Class period is from December 15, 2021, to September 16, 2025, with a lead plaintiff deadline of November 20, 2025 [2] - Allegations include materially false and misleading statements regarding tax fraud and bribery, which understated the legal risks and misled investors about the company's business prospects [2] Fortinet, Inc. (NASDAQ: FTNT) - Class period is from November 8, 2024, to August 6, 2025, with a lead plaintiff deadline of November 21, 2025 [3] - Allegations include misleading statements about the refresh cycle of products and the true number of upgradable firewalls, leading to materially misleading representations about the company's operations and prospects [3] Molina Healthcare, Inc. (NYSE: MOH) - Class period is from February 5, 2025, to July 23, 2025, with a lead plaintiff deadline of December 2, 2025 [4] - Allegations include failure to disclose adverse facts regarding medical cost trend assumptions and the company's financial guidance, which were materially misleading to investors [4] Marex Group plc (NASDAQ: MRX) - Class period is from May 16, 2024, to August 5, 2025, with a lead plaintiff deadline of December 8, 2025 [5] - Allegations include selling over-the-counter financial instruments to itself and inconsistencies in financial statements, leading to materially misleading representations about the company's business and operations [6]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Molina Healthcare, Inc. due to alleged violations of federal securities laws, encouraging affected investors to contact them before the December 2, 2025 deadline for lead plaintiff applications in a federal securities class action [4][6]. Summary by Sections Company Overview - Molina Healthcare, Inc. is a publicly traded company on the NYSE under the ticker MOH [4]. Allegations and Financial Impact - The complaint alleges that Molina and its executives made false or misleading statements regarding the company's medical cost trend assumptions and financial guidance for fiscal year 2025 [6]. - Specific issues cited include a dislocation between premium rates and medical costs, reliance on low utilization of various health services, and the likelihood of cutting financial guidance [6]. Financial Results and Stock Performance - On July 7, 2025, Molina announced second-quarter results with adjusted earnings of approximately $5.50 per share, leading to a 10.2% cut in full-year earnings guidance from at least $24.50 to a range of $21.50 to $22.50 per share [7]. - Following this announcement, Molina's stock price fell by $6.97, or 2.9%, closing at $232.61 per share [7]. - On July 23, 2025, Molina further reduced its full-year earnings guidance, reporting a GAAP net income of $4.75 per diluted share for the second quarter, an 8% decrease year-over-year, and cutting guidance to no less than $19.00 per diluted share [8][9]. - This led to a significant stock price drop of $32.03, or 16.84%, closing at $158.22 per share on July 24, 2025 [9]. Legal Proceedings - The deadline for investors to seek the role of lead plaintiff in the class action is December 2, 2025 [4]. - Any member of the putative class can move the court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [10]. Call for Information - Faruqi & Faruqi encourages anyone with information regarding Molina's conduct, including whistleblowers and former employees, to contact them [11].

Core Viewpoint - A securities class action lawsuit has been filed against Molina Healthcare, Inc. for allegedly making false and misleading statements regarding its financial health and operational performance during the Class Period from February 5, 2025, to July 23, 2025 [1][2]. Summary by Relevant Sections Allegations Against Defendants - The complaint claims that Molina's management failed to disclose critical adverse facts about the company's medical cost trend assumptions [2] - It is alleged that Molina was facing a dislocation between premium rates and medical cost trends [2] - The company's near-term growth was reportedly reliant on a lack of utilization of behavioral health, pharmacy, and inpatient and outpatient services [2] - As a result of these issues, Molina's financial guidance for fiscal year 2025 was likely to be significantly reduced [2] - The positive statements made by Molina's management regarding the company's business and prospects were deemed materially misleading and lacking a reasonable basis [2] Lead Plaintiff Process - Investors in Molina have until December 2, 2025, to seek appointment as a lead plaintiff representative for the class [3] - A lead plaintiff acts on behalf of all class members and typically has the largest financial interest in the case [3] - The decision to serve as a lead plaintiff does not affect an investor's ability to share in any recovery [3] Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [4] - The firm aims to protect investors and consumers from fraud and negligence by businesses [4]

Core Insights - The article compiles significant research calls from Wall Street, highlighting upgrades and downgrades of various companies that investors should be aware of [1] Upgrades - BofA upgraded Sea Limited (SE) to Buy from Neutral with a price target of $215, increased from $206, citing strong momentum across its businesses [2] - JPMorgan upgraded Las Vegas Sands (LVS) to Overweight from Neutral with a price target of $60, up from $56, due to a recent pullback in shares and a positive outlook for Singapore [2] - JPMorgan also upgraded PPG (PPG) to Overweight from Neutral, maintaining a price target of $112, believing that PPG's market value has decreased more than its business fundamentals [3] - Seaport Research upgraded TKO Group (TKO) to Buy from Neutral with a price target of $214, becoming more constructive after recent share pullbacks [3] - Wells Fargo upgraded T-Mobile (TMUS) to Overweight from Equal Weight with a price target of $260, up from $250, due to higher expected free cash flow growth and network leadership [4] Downgrades - Bernstein downgraded Lululemon (LULU) to Market Perform from Outperform with a price target of $190, down from $220, citing worsening underlying U.S. trends despite a near-term boost from promotions [5] - TD Cowen downgraded Molina Healthcare (MOH) to Hold from Buy, maintaining a price target of $203, due to potential medical loss ratio pressure from state budget deficits [5] - Deutsche Bank downgraded Fiserv (FI) to Hold from Buy with a price target of $122, down from $175, anticipating a lower 2025 outlook amid deteriorating fundamentals [5] - Rothschild & Co Redburn downgraded Verisk Analytics (VRSK) to Sell from Neutral with a price target of $220, indicating that downside risks are not reflected in the shares [5] - Goldman Sachs downgraded Cricut (CRCT) to Sell from Neutral with a price target of $4.75, down from $5.50, due to limited visibility into sustainable revenue growth beyond 2026 [5]

Core Viewpoint - A lawsuit has been filed against Molina Healthcare, Inc. and its senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Group 1: Lawsuit Details - Investors have until December 2, 2025, to request to lead the case, which is pending in the U.S. District Court for the Central District of California [2]. - The lawsuit is titled Hindlemann v. Molina Healthcare, Inc., et al., No. 25-cv-9461 [2]. Group 2: Company Background - Molina Healthcare is a health insurance company that provides managed healthcare services to low-income individuals under Medicaid and Medicare programs [3]. - The company previously claimed a "solid" earnings growth profile heading into 2025 and stated it was able to mitigate healthcare cost inflation [3]. Group 3: Financial Performance and Stock Impact - On July 7, 2025, Molina reported Q2 2025 adjusted earnings of approximately $5.50 per share, which was below prior expectations due to medical cost pressures across all business lines [4]. - The company cut its guidance for expected adjusted earnings per share by 10.2%, revising it to a range of $21.50 to $22.50 per share [4]. - Following further revelations on July 23, 2025, regarding a challenging medical cost trend environment, Molina's stock price fell by $32.03 per share, or 16.8%, from $190.25 to $158.22 [4].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Molina Healthcare, Inc. securities between February 5, 2025, and July 23, 2025, due to undisclosed adverse facts affecting the company's financial guidance and operations [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Molina Healthcare failed to disclose material adverse facts regarding its medical cost trend assumptions and the dislocation between premium rates and medical costs [5]. - The lawsuit alleges that Molina's near-term growth relied on a lack of utilization of various health services, which was not communicated to investors [5]. - As a result of these undisclosed facts, Molina's financial guidance for fiscal year 2025 was likely to be cut, leading to misleading positive statements about the company's business and prospects [5]. Group 2: Participation Information - Investors who purchased Molina securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact the law firm directly for more information [3][6]. - A lead plaintiff must move the Court by December 2, 2025, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field [4]. - The firm has recovered hundreds of millions of dollars for investors, with notable achievements in 2019 and 2020 [4]. - Investors are encouraged to select qualified counsel with a proven success record, as many firms may lack comparable experience [4].

Core Viewpoint - Molina Healthcare, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives failed to disclose critical financial information during the class period from February 5, 2025, to July 23, 2025 [1][3]. Group 1: Allegations and Financial Impact - The lawsuit alleges that Molina Healthcare did not disclose adverse facts regarding its medical cost trend assumptions and the dislocation between premium rates and medical costs [3]. - It is claimed that Molina's near-term growth relied on low utilization of various healthcare services, which was not communicated to investors [3]. - Following the announcement of second quarter 2025 adjusted earnings of approximately $5.50 per share, which was below expectations due to medical cost pressures, Molina cut its earnings guidance by 10.2% at the midpoint [4]. - On July 23, 2025, Molina reported a GAAP net income of $4.75 per diluted share for the second quarter, an 8% decrease year-over-year, and revised its full-year 2025 adjusted earnings expectation to no less than $19.00 per diluted share [5]. Group 2: Class Action Process - Investors who purchased Molina Healthcare securities during the class period can seek appointment as lead plaintiff in the class action lawsuit, which allows them to act on behalf of other class members [6]. - The lead plaintiff can select a law firm of their choice to represent the class in the lawsuit [6]. Group 3: About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [7]. - The firm has been recognized for securing the most monetary relief for investors in securities class action cases, ranking 1 in the ISS Securities Class Action Services rankings for four out of the last five years [7].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Molina Healthcare, Inc. due to alleged violations of federal securities laws, particularly concerning misleading statements about the company's financial health and medical cost trends [3][4]. Summary by Sections Company Overview - Molina Healthcare, Inc. is a publicly traded company on the NYSE under the ticker MOH [1]. Allegations - The complaint alleges that Molina and its executives made false or misleading statements regarding: - Material adverse facts about the company's medical cost trend assumptions [3]. - A dislocation between premium rates and medical costs [3]. - Dependency on low utilization of behavioral health and other services for near-term growth [3]. - Likelihood of substantial cuts to financial guidance for fiscal year 2025 [3]. - Misleading positive statements about the company's business and operations [3]. Financial Performance - On July 7, 2025, Molina announced second-quarter results, reporting adjusted earnings of approximately $5.50 per share, which was below prior expectations due to medical cost pressures [4]. - The company cut its full-year 2025 adjusted earnings guidance by 10.2%, revising it from at least $24.50 per share to a range of $21.50 to $22.50 per share [4]. - Following this announcement, Molina's stock price fell by $6.97, or 2.9%, closing at $232.61 per share [4]. Further Guidance Cuts - On July 23, 2025, Molina further reduced its full-year 2025 earnings guidance, expecting adjusted earnings to be no less than $19.00 per diluted share, representing a 13.6% cut from previous guidance [5]. - The company also cut its full-year GAAP net income guidance by 27% to $912 million [5]. - Following this news, Molina's stock price dropped by $32.03, or 16.84%, closing at $158.22 per share [5].

, /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Molina Healthcare, Inc. ("Molina " or "the Company") (NYSE: MOH ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of MOH during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not requ ...

Core Viewpoint - A class action lawsuit has been filed against Molina Healthcare, Inc. regarding allegations of securities fraud and unlawful business practices [2][4]. Financial Performance - On July 7, 2025, Molina reported second quarter adjusted earnings of approximately $5.50 per share, which was below prior expectations due to medical cost pressures across all business lines [4]. - Molina cut its full year 2025 adjusted earnings per share guidance by 10.2% at the midpoint, revising it from at least $24.50 per share to a range of $21.50 to $22.50 per share [4]. - Following this announcement, Molina's stock price fell by $6.97 per share, or 2.9%, closing at $232.61 per share [4]. Subsequent Guidance Adjustments - On July 23, 2025, Molina further reduced its full-year 2025 earnings guidance, now expecting adjusted earnings to be no less than $19.00 per diluted share, representing a 13.6% cut from the previous guidance [5]. - The company's GAAP net income for the second quarter was reported at $4.75 per diluted share, an 8% decrease year over year [5]. - Molina also cut its full year 2025 GAAP net income guidance by 27% to $912 million, attributing the results to a challenging medical cost trend environment [5]. - Following this news, Molina's stock price dropped by $32.03 per share, or 16.84%, closing at $158.22 per share [5].